683 Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

683 Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6,960	Closed	-$203K	–	324
2022 Q4	$203K	Buy	+6,960	New	+$179K	0.02%	161

Other funds holding RYTM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

683 Capital Management's RYTM Position: Q1 2023 in Review

683 Capital Management sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2023, closing a stake of 6,960 shares — an estimated $203K sold.

683 Capital Management first reported a position in RYTM in Q4 2022 and held it in 1 quarter. The position peaked at $203K in Q4 2022. 126 funds tracked by Wall St. Rank hold RYTM as of Q1 2023.

683 Capital Management reported no remaining Rhythm Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
683 Capital Management sold 6,960 Rhythm Pharmaceuticals shares in Q1 2023, an estimated $203K.
683 Capital Management first reported a position in Rhythm Pharmaceuticals in Q4 2022 and held it in 1 quarter.
683 Capital Management's Rhythm Pharmaceuticals position peaked at $203K in Q4 2022.
126 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2023.

Based on 683 Capital Management's 13F filing for Q1 2023, filed 15 May 2023.